(RTTNews) - Corbus Pharmaceuticals Holdings, Inc. (CRBP) Tuesday announced FDA clearance for its investigational new drug or IND application of CRB-601, a TGFß blocking monoclonal antibody targeting the integrin avß8.
The Oncology company said CRB-601 could overcome tumor immune exclusion and enhance the activity of immune checkpoint inhibitors in vivo. The company expects to enroll the first participant in a Phase 1 study in the first half of 2024.
Corbus said it will initiate Phase 1 First-in-Human trial of CRB-601 and to enroll the first participant in the first half of this year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
